Sartorius Stedim Biotech SA: Information on Document Availability
July 21, 2023 at 06:08 am
Share
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
21-Jul-2023 / 07:05 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Aubagne, July 21, 2023
Information on Document Availability
The report on the first half 2023 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
Business development for the period of January to June 2023 as well as the 2023 full year forecast for the Sartorius Stedim Biotech Group
Consolidated financial statements for the period ended June 30, 2023
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2022, the company employed more than 12,000 people, and earned sales revenue of around 3.5 billion euros.
Contact
Petra Müller
Head of Investor Relations
+49 (0)551.308.6035
petra.mueller2@sartorius.com
Regulatory filing PDF file
File: Information on Document Availability
Language:
English
Company:
Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:
+33 44 284 5600
E-mail:
sartorius.presse@sartorius.com
Internet:
www.sartorius-stedim.com
ISIN:
FR0013154002
Euronext Ticker:
DIM
AMF Category:
Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
SARTORIUS STEDIM BIOTECH 
